Baum M et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98(9):1802-10. Abstract

Bliss J et al. First mature analysis of the Intergroup Exemestane Study. Presentation. ASCO 2006;Abstract LBA 527.

Boccardo F et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23(22):5138-47. Abstract

Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol 2006;33(Suppl):13-7. Abstract

Buzdar AU, on behalf of the ATAC Trialists’ Group. Clinical features of joint symptoms observed in the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial. Proc ASCO 2006;Abstract 551.

Coleman RE, on behalf of the ATAC Trialists’ Group. Effect of anastrozole on bone mineral density: 5-year results from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial. Proc ASCO 2006;Abstract 511.

Coombes RC et al; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract

Cuzick J et al. A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years’ treatment. San Antonio Breast Cancer Symposium 2006;Abstract 104.

Cuzick J et al. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomized prevention trial. Lancet 2002;360:817-24. Abstract

Davidson B et al. How conversations about adjuvant hormonal therapy differ from ‘typical’ oncology discussions: Results of an observational linguistic study. Proc ASCO 2006;Abstract 6141.

Duffy S et al. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: First results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2006;21(2):545-53. Abstract

Duffy S et al. Anastrozole is associated with a lower risk of endometrial abnormalities than tamoxifen: First report of the ATAC trial endometrial sub-protocol at 6 years follow-up. San Antonio Breast Cancer Symposium 2006;Abstract 4055.

Duffy S et al. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: Baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy. Hum Reprod 2005;20(1):294-301. Abstract

Eastell R et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006;21(8):1215-23. Abstract

Francini G et al. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: Effects on body composition and lipids. Br J Cancer 2006;95(2):153-8. Abstract

Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97(17):1262-71. Abstract

Goss PE et al. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding. San Antonio Breast Cancer Symposium 2005;Abstract 16.

Horton J. 1995 Oxford breast cancer overview — Preliminary outcomes. Cancer Control 1996;3:78-9. Abstract

Howell A, on behalf of the ATAC Trialists’ Group. Analysis of fracture risk factors from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: 5-year data. Proc ASCO 2006;Abstract 563.

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Ingle JN et al. Analysis of duration of letrozole extended adjuvant therapy as measured by hazard ratios of disease recurrence over time for patients on NCIC CTG MA.17. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 17.

Jakesz R et al; ABCSG and GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366(9484):455-62. Abstract

Jonat W et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: A meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial. San Antonio Breast Cancer Symposium 2005;Abstract 18.

Land SR et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006;295:2742-51. Abstract

Owusu C et al. Tamoxifen discontinuance among women aged 65 years and older with estrogen receptor positive breast cancer. Proc ASCO 2006;Abstract 648.

Partridge AH et al. Adherence with adjuvant anastrozole therapy among women with early stage breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 4044.

Partridge AH et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21(4):602-6. Abstract

Perez EA et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17. J Clin Oncol 2006;24(22):3629-35. Abstract

Robert NJ et al. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding. Proc ASCO 2006;Abstract 550.

Singh S et al. Effect of anastrozole on cholesterol fractions in postmenopausal women with a high risk of breast cancer: Results from IBIS-II breast cancer prevention study. San Antonio Breast Cancer Symposium 2006;Abstract 1055.

Smith IE et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: Caution and suggested guidelines. J Clin Oncol 2006;24(16):2444-7. Abstract

The Arimidex, Tamoxifen, Alone or in Combination Trialists’ Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7(8):633-43. Abstract

Thürlimann B et al; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353(26):2747-57. Abstract